This diagnostics firm delivers precision molecular testing for prenatal and oncology use to hospitals and research centers.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of EDEN, a large, multi-center prospective study designed to evaluate the company’s non ...

BillionToOne Expands Its Leadership in Hemolytic Disease of the Fetus and Newborn (HDFN) and Extends Fetal Antigen Testing to Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) ...

During the fourth quarter of 2025, the largest portfolio sector weightings were Information Technology and Communication ...

Profits have also taken a tumble. The post Australian Clinical Labs shares hit record low as CEO to exit appeared first on The Motley Fool Australia.

Explore the Q4 2025 Alger Weatherbie Specialized Growth Fund performance. Read about the top contributors and detractors in ...

The prognosis for the cancer is poor. Five-year survival rates hover at about 49 per cent overall, dropping to less than 30 per cent when ovarian cancer is detected at stage four, which is common.

Global Fetal Monitoring Market OverviewThe global fetal monitoring market is expected to witness steady growth at a compound ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

Mercy BioAnalytics, Inc. ("Mercy"), a leader in advancing earlier and more accurate cancer detection, today announced the appointment of Darrin Crisitello as Chief Commercial Officer. Mr. Crisitello ...

Natera NTRA recently announced the submission of a premarket approval (PMA) application to the FDA for its Signatera CDx test ...

A Las Vegas couple's dream of being parents becomes a nightmare when DNA tests reveal a surrogacy shock, sparking a legal ...